Ace Therapeutics, a preclinical contract research organization specializing in analgesic drug research, announced its comprehensive end-to-end solutions for pain therapeutic development. The platform features a broad range of validated in vivo pain models and a complete suite of preclinical research capabilities designed to support pharmaceutical and biotechnology customers worldwide.
Covering every stage from early target discovery and mechanism verification through pharmacological validation and safety assessment, Ace Therapeutics' services address the complex demands of modern pain drug research. The company utilizes integrated in vitro and in vivo research platforms to study physiological pain mechanisms, evaluate compound efficacy, and conduct safety profiling for novel analgesic candidates.
A core strength is the extensive portfolio of standardized and customized in vivo pain models for drug testing, spanning nearly all mainstream pain classifications. These validated animal models include migraine models established via trigeminal ganglion electrical stimulation and nitroglycerin induction, as well as multiple neuropathic pain models such as spinal nerve ligation, chronic constriction injury, and diabetic neuropathic pain models.
To complement its in vivo systems, Ace Therapeutics offers systematic preclinical pain assessment services including mechanical pain, thermal pain, chemical pain, cold pain, and electrical stimulation pain assessments using well-established methods like the Von Frey Filament Test, Hot Plate Test, and Formalin Test. Additionally, in vitro neuropathic pain model development services leverage dorsal root ganglion (DRG) cells, iPSC-derived sensory neurons, and co-culture systems to explore pain-related cellular mechanisms, enhancing the translational value of preclinical research.
Beyond model construction and efficacy testing, the preclinical analgesic drug development services extend to target-based and modality-based drug discovery. These services support research targeting G-protein coupled receptors, cytokine networks, and various ion channels, delivering solutions for small-molecule analgesics, biologics including antibodies, recombinant proteins, peptides, cell therapies, and gene therapy candidates. The platform also offers mechanism-driven research covering peripheral inflammatory pathways, central regulatory pathways, neuronal signaling pathways, and neuro-immune interaction pathways.
The full-service pipeline includes target validation, in vitro screening, in vivo pharmacology research, pharmacokinetics analysis, safety pharmacology, preclinical formulation development, and biomarker discovery. Professional PK/PD modeling, toxicity assessment, and formulation optimization help clients reduce research risks, determine optimal dosages, and accelerate candidate selection for analgesic drugs. For special research needs, Ace Therapeutics can design customized pain models and testing assays according to unique drug mechanisms and research objectives.
